We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.50 | 17.00 | 18.00 | 17.50 | 17.50 | 17.50 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.16 | 15.96M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/11/2017 09:00 | Indeed! You get the sense that the company is bursting to tell us more but can't for obvious reasons. Although nothing new, the "US partners" and "large retailers" comments are hugely exciting. | colinzeal | |
08/11/2017 08:59 | Get us on Nasdaq where the story will be much more appreciated by a much wider audience Aim Cesspit isn’t for Opti imho | judijudi | |
08/11/2017 08:56 | If they have any sense at all...they’ll give this a very wide miss, at least until there’s a sign of income/profit! | rayrac | |
08/11/2017 08:52 | These new products are most likely from developments coming from the sugar division. The oligofructose prebiotic fibre which is currently in slimbiome can be changed to specific sugars that impact on other areas of health. We probably hear a fraction of what's actually going on behind the scenes. | riskybusiness1 | |
08/11/2017 08:48 | Early in the day so no worries on the share price reaction. I do think Jo public is being far more careful with his cash atm. This means some will wait until the revenues appear on the balance sheet no doubt. | rafboy | |
08/11/2017 08:29 | But...but Chris has a lot of expertise, he would know this.. | loungeact | |
08/11/2017 08:24 | Chris - from this article, it would appear a peer review is a process of scrutiny not a publication: | m4rtinu | |
08/11/2017 08:20 | I cannot understand anybody selling at this pivotal time in our history What a perfect time to be buying, not selling | judijudi | |
08/11/2017 08:16 | Unfortunately at present, investors, the market just isnt listening.Volume and interest has been very low despite some excellent news. | john henry | |
08/11/2017 08:16 | Bought some....5.000 I am very suprised at the lack of buying. I expect some want a diagram to go with the r.n.s. | bobdown2 | |
08/11/2017 08:03 | ImmunBiome.... whats that all about? have we found another holy grail. surely we have not discovered the biome that enhances the immune defences. this is mind boggling if we have. Elrico can you contact SOH to see if there is any expansion on this line of investigation? Wreckage | wreckage | |
08/11/2017 08:01 | General Mills and Kellogg's via CII anyone? Neither US company have the ability to manufacture their own ingredients. I'm pretty confident they get their ingredients from CII. Knighton Foods - commercial basket case ;) | elrico | |
08/11/2017 07:55 | There’s one thing we lths share with mmouse: a sense of anticipation and of excitement when an rns is flagged. | owenmo | |
08/11/2017 07:52 | Well being section in boots? | shrewdmole | |
08/11/2017 07:52 | Wow, so many uses and so many revenue streams coming our way. Love it. | rafboy | |
08/11/2017 07:45 | This latest RNS could well be the one that completes the share price consolidation to close today at/above 74p, then we should finally be off and away on the journey North. The two small retracements during this last week have been on notably low volume.Oh....... And I love the products news! | tightfist | |
08/11/2017 07:33 | I love the move into coffee and tea blends! | jestercat2 | |
08/11/2017 07:15 | We anticipate SlimBiome(R) being the first in a family of products to include: ImmunBiome, WellBiome, OptiBiome(R) and CardioBiome(R), developed.Lots of new ingredients announced! I get the impression SlimBiome could become more valuable than initially envisaged.Must admit I am loving these weekly RNS! | parob | |
08/11/2017 07:07 | Yet another positive update and more potential revenue streams. Talk of cookies and tortillas suggests the US market! All coming together. | deeppockets | |
08/11/2017 00:19 | Loungeact Can't understand any of that loungeact so someone else needs to translate. If I understand elrico correctly I have been after a study that's not actually been published yet so no wonder I can't find it! I'm only teasing elrico a bit over wanting to see peer reviews because he mentions them so often. I doubt the review comments are available anyway. Peer reviewing before publication. I suppose is the standard but does have its failings and journals seem to like it. I simply want to have a look at the study write up when it's published and see where these relatively low percentage improvements come from in BP and cholesterol and to form a practical clinical view on this potentially exciting development. I am not a detractor of the science as you and others believe. The science at times is a bit complex even for me but I am mainly interested in how this will translate into 'clinical benefit' to people compared with pharmaceuticals. I've mentioned it before and even the enthusiasts didn't seem to realise it that if indeed a food additive/probiotic with or without a catalyst can significantly and with proven clinical preventative benefit lower both cholesterol and BP it is one of the discoveries of the century. I am a guarded enthusiast and I think some on here have got me all wrong following my alternative but more accurate analysis of Dr Adnan's cholesterol results! I cannot wait to see if the good doctor will give us his next cholesterol result because that may be the moment of truth! | chrisg11 | |
07/11/2017 23:57 | Paul - You ask a very good question. I gather our resident Victor Meldrew is continuing with his "I demand to see the peer review" and I am not going to have the wool pulled over my eyes by man nor beast, and definitely by that lapdog Elrico. Perhaps Chris is desperate to portray he has a superior grasp of the science behind the LP-LDL and wants to impart his wisdom. Perhaps Chris has some advise he wishes to share with the authors, Prof Glen Gibson and Pro John Swann. I opened the door for anyone wanting info. All he has to do is PM me with his email address and I'll furnish him with everything I have on the subject, including the documentation used at the Probiota conference which was used in the peer review. Has Chris got round to explaining where he magicked my 6 figure investment from? No! Just as I suspected. It is like asking Michaelmouse to explain his accounting deceptions I debunked - they remain unanswered also. Perhaps I'll get answers to all of them in a Christmas card. | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions